CorMedix (CRMD)

• Market cap: $594M
• 1 day: 0.66%
• 5 days: 5.07%
• 1 month: 48.05%
• 3 months: -19.22%
• 6 months: -29.68%
• Year to date: 10.95%
• 1 year: 72.73%
• 5 years: 108.70%
• 10 years: -76.85%
• Sector: Healthcare
• Industry: Biotechnology

About: Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.

Employees: 82

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

264% more first-time investments, than exits

New positions opened: 40 | Existing positions closed: 11

104% more repeat investments, than reductions

Existing positions increased: 49 | Existing positions reduced: 24

66% more call options, than puts

Call options by funds: $6.64M | Put options by funds: $4M

26% more funds holding

Funds holding: 102 [Q3] → 129 (+27) [Q4]

20% more capital invested

Capital invested by funds: $155M [Q3] → $186M (+$31.4M) [Q4]

3.55% more ownership

Funds ownership: 34.28% [Q3] → 37.83% (+3.55%) [Q4]

50% less funds holding in top 10

Funds holding in top 10: 2 [Q3] → 1 (-1) [Q4]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $12 32% upside
• Avg. target: $14.25 56% upside
• High target: $18 97% upside

4 analyst ratings

• positive: 4 100%
• neutral: 0 0%
• negative: 0 0%

Needham Serge Belanger 51% 1-year accuracy 63 / 124 met price target	32% upside $12	Buy Reiterated	9 Apr 2025
D. Boral Capital Jason Kolbert 28% 1-year accuracy 103 / 373 met price target	64% upside $15	Buy Maintained	8 Apr 2025
RBC Capital Gregory Renza 27% 1-year accuracy 20 / 75 met price target	32% upside $12	Outperform Reiterated	26 Mar 2025
Leerink Partners Roanna Ruiz 22% 1-year accuracy 2 / 9 met price target	97% upside $18	Outperform Initiated	7 Mar 2025